Cardiff Oncology Stock Price Prediction
| CRDF Stock | USD 3.55 0.18 4.83% |
Momentum 66
Buy Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.19) | EPS Estimate Current Year (0.82) | EPS Estimate Next Year (0.93) | Wall Street Target Price 12.0714 | EPS Estimate Current Quarter (0.19) |
Using Cardiff Oncology hype-based prediction, you can estimate the value of Cardiff Oncology from the perspective of Cardiff Oncology response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Cardiff Oncology using Cardiff Oncology's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Cardiff using crowd psychology based on the activity and movement of Cardiff Oncology's stock price.
Cardiff Oncology Short Interest
A significant increase or decrease in Cardiff Oncology's short interest from the previous month could be a good indicator of investor sentiment towards Cardiff. Short interest can provide insight into the potential direction of Cardiff Oncology stock and how bullish or bearish investors feel about the market overall.
200 Day MA 3.442 | Short Percent 0.2916 | Short Ratio 13.17 | Shares Short Prior Month 18.4 M | 50 Day MA 3.5684 |
Cardiff Oncology Hype to Price Pattern
Investor biases related to Cardiff Oncology's public news can be used to forecast risks associated with an investment in Cardiff. The trend in average sentiment can be used to explain how an investor holding Cardiff can time the market purely based on public headlines and social activities around Cardiff Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Cardiff Oncology's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Cardiff Oncology.
Cardiff Oncology Implied Volatility | 2.1 |
Cardiff Oncology's implied volatility exposes the market's sentiment of Cardiff Oncology stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cardiff Oncology's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cardiff Oncology stock will not fluctuate a lot when Cardiff Oncology's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Cardiff Oncology to buy its stock at a price that has no basis in reality. In that case, they are not buying Cardiff because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cardiff Oncology after-hype prediction price | USD 3.77 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Cardiff Oncology Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiff Oncology After-Hype Price Prediction Density Analysis
As far as predicting the price of Cardiff Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cardiff Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cardiff Oncology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cardiff Oncology Estimiated After-Hype Price Volatility
In the context of predicting Cardiff Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cardiff Oncology's historical news coverage. Cardiff Oncology's after-hype downside and upside margins for the prediction period are 0.19 and 8.80, respectively. We have considered Cardiff Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cardiff Oncology is relatively risky at this time. Analysis and calculation of next after-hype price of Cardiff Oncology is based on 3 months time horizon.
Cardiff Oncology Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Cardiff Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiff Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cardiff Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.64 | 5.14 | 0.03 | 0.04 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.55 | 3.77 | 1.07 |
|
Cardiff Oncology Hype Timeline
Cardiff Oncology is currently traded for 3.55. The entity has historical hype elasticity of 0.03, and average elasticity to hype of competition of -0.04. Cardiff is forecasted to increase in value after the next headline, with the price projected to jump to 3.77 or above. The average volatility of media hype impact on the company the price is over 100%. The price rise on the next news is projected to be 1.07%, whereas the daily expected return is currently at 0.64%. The volatility of related hype on Cardiff Oncology is about 7821.74%, with the expected price after the next announcement by competition of 3.51. The company reported the previous year's revenue of 683 K. Net Loss for the year was (45.43 M) with loss before overhead, payroll, taxes, and interest of (38.73 M). Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Cardiff Oncology Basic Forecasting Models to cross-verify your projections.Cardiff Oncology Related Hype Analysis
Having access to credible news sources related to Cardiff Oncology's direct competition is more important than ever and may enhance your ability to predict Cardiff Oncology's future price movements. Getting to know how Cardiff Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cardiff Oncology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GNPX | Genprex | 0.01 | 10 per month | 5.95 | 0.04 | 11.54 | (9.37) | 38.82 | |
| RVPH | Reviva Pharmaceuticals Holdings | (0.08) | 7 per month | 0.00 | (0.04) | 11.76 | (9.28) | 69.49 | |
| GLSI | Greenwich Lifesciences | (0.26) | 6 per month | 2.68 | 0.04 | 6.35 | (5.27) | 16.78 | |
| CGTX | Cognition Therapeutics | (0.03) | 9 per month | 6.48 | 0.14 | 20.59 | (12.50) | 60.03 | |
| PDSB | PDS Biotechnology Corp | 0.04 | 9 per month | 4.59 | (0.01) | 8.51 | (8.27) | 21.14 | |
| LPTX | Leap Therapeutics | (0.1) | 8 per month | 5.20 | (0.03) | 8.11 | (9.52) | 30.19 | |
| CRVS | Corvus Pharmaceuticals | (0.04) | 9 per month | 3.96 | 0.08 | 6.61 | (7.51) | 41.22 |
Cardiff Oncology Additional Predictive Modules
Most predictive techniques to examine Cardiff price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cardiff using various technical indicators. When you analyze Cardiff charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cardiff Oncology Predictive Indicators
The successful prediction of Cardiff Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cardiff Oncology, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cardiff Oncology based on analysis of Cardiff Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cardiff Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cardiff Oncology's related companies. | 2022 | 2024 | 2025 (projected) | Dividend Yield | 0.006782 | 0.0078 | 0.00741 | Price To Sales Ratio | 158.13 | 302.78 | 203.72 |
Story Coverage note for Cardiff Oncology
The number of cover stories for Cardiff Oncology depends on current market conditions and Cardiff Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cardiff Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cardiff Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cardiff Oncology Short Properties
Cardiff Oncology's future price predictability will typically decrease when Cardiff Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cardiff Oncology often depends not only on the future outlook of the potential Cardiff Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cardiff Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.6 M | |
| Cash And Short Term Investments | 91.7 M |
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |